Assessment of "contrat de bon usage" on 4 years period: Conformity to guidelines - Experience of anti-TNFα;Bilan de 4 ans du contrat de bon usage: Conformité aux référentiels - Cas des anti-TNFα

Therapie

Volumn 63, Issue 4, 2008, Pages 281-289

  Plard, Christine ^a   Serry, Géraldine ^a   Faure, Pierre ^a   Madelaine Chambrin, Isabelle ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Adalimumab; Etanercept; Guidelines; Infliximab; Pharmacoeconomics

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; DISEASE SEVERITY; DRUG INDICATION; DRUG USE; HISTIOCYTOSIS; HUMAN; MAJOR CLINICAL STUDY; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PUVA; RHEUMATOID ARTHRITIS; SARCOIDOSIS;

EID: 55049116154     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2008051     Document Type: Article

References (27)

1. Ferrari-Lacraz S. Intérêt des thérapies biologiques dans les maladies autoimmunes. Med Hyg 2004; 2471: 443-9
2. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Bio-drugs 2002; 16: 111-48
3. Circulaire no 2001-570 du 28/01/01 relative à la campagne budgétaire pour 2001 des établissements de santé sous dotation globale. http://www.legifrance.gouv.fr
4. Arrêté du 4 avril 2005 pris en application de l'article L.162-22-7 du code de la sécurité sociale et fixant la liste des spécialités pharmaceutiques prises en charge par l'assurance maladie en sus des prestations d'hospitalisation. http://www.legifrance.gouv.fr
5. Décret no 2005-1023 du 24/08/05 relatif au contrat de bon usage des médicaments et des produits et prestations mentionné à l'article L.162-22-7 du code de la sécurité sociale. http://www.legifrance.gouv.fr
6. Site du comité de la Juste Prescription : http://jprescription. aphp.fr
7. Rouleau A, Metman EH, Goupille P. Suivi de l'utilisation des anti-TNF alpha (Infliximab, Etanercept) par le Comité Régional du Médicament et des Dispositif Médicaux de la région Centre. Synoviale 2003; 121: 43-48
8. Gallini Adeline. Les anti-TNF alpha en Midi-Pyrénées. Étude d'utilisation pour la polyarthrite rhumatoïde. Thèse d'exercice de pharmacie, 11 septembre 2006 (Université Toulouse III, Paul Sabatier)
9. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa : transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-8
10. Henter JI, Karlen J, Calming U, et al. Successful treatment of Langerhans-cell histiocytosis with etanercept. N Engl J Med 2001; 345: 1577-8
11. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94
12. Van den Brande JMH, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85
13. Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α. Gastroenterology 2004; 126: 934-5
14. Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparaison of efficacy of the tumor necrosis factor ? blocking agents adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62: ii13-ii16
15. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007; 26: 1237-54
16. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-TNFα agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67: 1229-34
17. Atzeni F, Doria A, Carrabba M, et al. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmum Rev 2007; 6: 529-36
18. Feldmann M, Pusey CD. Is there a role for TNF-α in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 2006; 17: 1243-52
19. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-9
20. Jacobsohn DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74: 119-24
21. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73: 665-7
22. Bay JO, Cabrespine A, Peffault de Latour R. Place des anticorps monoclonaux dans le traitement de la maladie aiguë du greffon contre l'hôte en 2006. Bull Cancer 2007; 94: 33-41
23. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-4
24. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2003; 2: 413-4
25. Mallbris L, Ljungberg A, Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2003; 48: 290-3
26. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 2005; 141: 910-1
27. Rosen T, Doherty C. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion. Dermatol Online J 2007; 13: 14 |letter]